Anne Hyland

Anne has served on the Board of Directors since March 2022. Anne was a non-executive director of Clinigen Group plc, a global pharmaceutical and services company and Chair of their Audit and Risk Committee until April 2022 when Clinigen was acquired by funds managed by Triton Investments. Anne was from 2013 to 2022 Chair of the Audit Committee and a non-executive director of Elementis plc, a global specialty chemicals company. Anne was Chief Financial Officer and Company Secretary of Kymab Group Ltd a biopharmaceutical company acquired by Sanofi in April 2021 for an upfront payment of US$1.1 billion and up to US$350 million in deferred consideration. Prior to this Anne had significant experience in biopharmaceutical companies, having worked as CFO and Company Secretary of BBI Diagnostics Group plc, a diversified global diagnostics business and Vectura Group plc, a company that develops therapeutic products and devices principally for the treatment of respiratory diseases. Anne previously held additional senior finance positions including director of corporate finance at the then FTSE 100 Celltech Group plc, Medeva plc and KPMG. Anne is a Chartered Accountant (FCA), a Corporate Tax Adviser (CTA – AITI) and holds a degree in business studies from Trinity College, Dublin.